drugset / Trial / NCT05195619
Personalized DC Vaccines in Non Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.
Timeline
- Start
- 2022-03-22
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEP-DC vaccine | Vaccine | 1.05 ml | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | — | — |